Drug Trial Radar · NCT05312021
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 2022
Primary completion
Sep 2023
Study completion Nov 2023
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Imara, Inc.
- First posted
- Apr 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The primary objective is to evaluate whether IMR-687 reduces NT-proBNP compared to placebo in these patients.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
IMR-687Drug
150 mg and 200 mg tablets
IMR-687 PlaceboOther
Matching placebo to IMR-687
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in NT-proBNPTime frame: Baseline to Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.